BeStock  
Stocks › Biotechnology › TVTX

Travere Therapeutic TVTX

US equityMarket cap rank #2128Biotechnology
$47.00 −$1.30 (-2.69%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $47.29 +0.62%
Open$48.09
Prev close$48.30
Day range$46.90 – $49.35
Volume1.33M
Market cap$4.51B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$224.56M+36.2% YoY
Operating profit$45.01M+80.5% YoY
Net profit-$52.34M-303.6% YoY
Diluted EPS-$0.55-296.4% YoY
Free cash flow-$43.66M-3,847.6% YoY
Operating cash flow$98.20M

Revenue, last 8 quarters

$74.8MDec '24$81.7MMar '25$114.4MJun '25$164.9MSep '25$129.7MDec '25$127.2MMar '26$169.6MJun '26$224.6MSep '26

Net profit, last 8 quarters

$-60.3MDec '24$-41.2MMar '25$-12.8MJun '25$25.7MSep '25$2.7MDec '25$-37.1MMar '26$-34.8MJun '26$-52.3MSep '26

Diluted EPS by quarter

-0.73Dec '24-0.47Mar '25-0.14Jun '250.28Sep '250.03Dec '25-0.40Mar '26-0.37Jun '26-0.55Sep '26

Free cash flow by quarter

$-45.3MDec '24$-54.0MMar '25$-7.1MJun '25$-1.1MSep '25$41.8MDec '25$-62.5MMar '26$37.0MJun '26$-43.7MSep '26

Annual revenue

$198.3MFY20$131.8MFY21$109.5MFY22$145.2MFY23$233.2MFY24$490.7MFY25

Profitability & balance sheet

Gross margin98.8%
Operating margin-3.1%
Net margin-18.7%
Return on equity-252.7%
Return on assets-17.5%
Return on invested capital-23.9%
Current ratio3.00
Liabilities / assets97.3%
Cash & investments$471.82M
Total debt$609.84M
Net cash (debt)-$138.03M

Where the revenue comes from

Quarter 2026/Q3

By business line

  • FILSPARI$200.19M 89.1%
  • Tiopronin products$20.00M 8.9%
  • License and collaboration revenue$4.37M 1.9%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $224.56M $169.58M $127.20M $490.73M $129.69M
Total Operating Revenue $224.56M $169.58M $127.20M $490.73M $129.69M
Cost of Revenue $10.84M $9.24M $26.77M $10.34M -$38.91M
Gross Profit $213.73M $160.35M $100.43M $480.39M $168.60M
Operating Expense $168.72M $156.40M $137.35M $543.21M $201.03M
Selling and Admin Expenses $98.41M $96.11M $80.25M $337.20M $143.16M
Research & Development $70.30M $60.28M $57.09M $206.01M $57.87M
Operating Profit $45.01M $3.95M -$36.92M -$62.82M -$32.43M
Net Non-Operating Interest Income (Expense) $1.56M $1.22M $284,000.00 $1.97M $296,000.00
Non-Operating Interest Income $3.70M $3.36M $2.58M $12.72M $2.59M
Non-Operating Interest Expense $2.14M $2.13M $2.30M $10.75M $2.30M
Other Income (Expense) -$113.51M -$40.18M -$91,000.00 $11.58M $11.07M
Special Income (Charges) -$113.12M – – $0.00 $0.00
-Less:Other Special Charges $113.12M – – – –
Other Non-Operating Income (Expenses) -$391,000.00 -$40.18M -$91,000.00 $11.58M $11.07M
Pretax Profit -$66.93M -$35.00M -$36.72M -$49.27M -$21.07M
Tax -$5.90M -$204,000.00 -$120,000.00 $988,000.00 $921,000.00
Net Profit -$52.34M -$34.80M -$37.10M -$25.55M $2.73M
Profit from Continuing Operations -$61.04M -$34.80M -$36.60M -$50.26M -$21.99M
Net Income from Discontinuous Operations $8.70M $0.00 -$500,000.00 $24.72M $24.72M
Net Income to Parent Company -$52.34M -$34.80M -$37.10M -$25.55M $2.73M
Net Income to Common Stockholders -$52.34M -$34.80M -$37.10M -$25.55M $2.73M
Basic EPS -$0.55 -$0.37 -$0.40 -$0.29 $0.03
Diluted EPS -$0.55 -$0.37 -$0.40 -$0.29 $0.03
-General & Admin Expense – $96.11M – $337.20M $101.69M
-Less:Restructuring and Mergern & Acquisition – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $848.23M $799.36M $555.19M $605.19M $605.19M
Total Current Assets $633.45M $615.14M $392.68M $437.57M $437.57M
Cash and Cash Equivalents & Short-Term Investments $471.82M $489.18M $264.68M $322.80M $322.80M
-Cash and Cash Equivalents $123.54M $117.74M $78.36M $93.04M $93.04M
-Short Term Investments $348.28M $371.44M $186.31M $229.76M $229.76M
Receivables $107.53M $80.64M $87.30M $80.13M $80.13M
-Accounts Receivable $107.53M $80.64M $87.30M $80.13M $80.13M
Inventory $10.52M $7.84M $6.36M $5.88M $5.88M
Other Current Assets $43.58M $37.49M $34.35M $28.76M $28.76M
Total Non-Current Assets $214.78M $183.47M $162.56M $166.87M $166.87M
Net PPE $10.53M $11.98M $13.30M $14.60M $14.60M
-Gross PPE $10.53M $11.98M $13.30M $24.70M $24.70M
Goodwill and Other Intangible Assets $164.11M $130.77M $110.09M $113.12M $113.12M
-Other Intangible Assets $164.11M $130.77M $109.29M $113.12M $113.12M
Other Non-Current Assets $40.14M $40.73M $39.17M $39.16M $39.16M
Total Liabilities $825.65M $774.84M $456.46M $490.36M $490.36M
Total Current Liabilities $210.91M $152.03M $125.44M $159.90M $159.90M
Payables $15.28M $7.50M $12.91M $24.80M $24.80M
-Accounts Payable $15.28M $7.50M $12.91M $24.80M $24.80M
Current Accrued Expenses $153.29M $110.48M $83.06M $84.52M $84.52M
Short-Term Debt and Capital Lease Obligation $6.31M $6.16M $6.02M $5.88M $5.88M
-Current Capital Lease Obligation $6.31M $6.16M $6.02M $5.88M $5.88M
Other Current Liabilities $2.10M $2.10M $2.10M $3.19M $3.19M
Total Non-Current Liabilities $614.73M $622.81M $331.02M $330.46M $330.46M
Long Term Debt and Capital Lease Obligation $609.84M $610.74M $321.65M $322.86M $322.86M
-Long Term Debt $603.51M $602.78M $312.08M $311.72M $311.72M
-Long Term Capital Lease Obligation $6.33M $7.96M $9.57M $11.13M $11.13M
Other Non-Current Liabilities $4.89M $12.07M $9.38M $7.60M $7.60M
Total Equity $22.58M $24.52M $98.73M $114.83M $114.83M
Stockholders' Equity $22.58M $24.52M $98.73M $114.83M $114.83M
Capital Stock $9,000.00 $9,000.00 $9,000.00 $9,000.00 $9,000.00
-Common Stock $9,000.00 $9,000.00 $9,000.00 $9,000.00 $9,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.62B $1.57B $1.61B $1.59B $1.59B
Retained Earnings -$1.60B -$1.54B -$1.51B -$1.47B -$1.47B
Gains/Losses Not Affecting Retained Earnings -$2.05M -$1.12M -$1.06M -$1.19M -$1.19M
-Goodwill – – $800,000.00 – –
-Accumulated Depreciation – – – -$10.10M -$10.10M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $98.20M $58.07M -$40.37M $37.78M $60.68M
Net cash flow from continuing operations $74.70M $58.07M -$40.37M $37.78M $60.68M
Net Income from Continuing Operations -$61.04M -$34.80M -$36.60M -$50.26M -$21.99M
Gain/Loss from Continuing Operations $113.53M – – – –
Depreciation & Depletion & Amortization $5.20M $4.23M $25.21M $60.74M $18.14M
Other Non-Cash Items -$1.01M $37.40M -$4,000.00 $183,000.00 $1.68M
Change in Working Capital -$5.42M $28.50M -$45.12M -$14.00M $52.67M
-Change in Receivables -$41.92M $6.64M -$7.23M -$26.97M $28.67M
-Change in Inventory -$2.60M -$2.71M -$742,000.00 $5.02M $1.18M
-Change in Prepaid Assets -$3.01M -$3.08M -$6.38M -$7.66M $446,000.00
-Change in Payables and Accrued Expense $49.04M $24.69M -$32.71M $28.76M $23.59M
-Change in Other Current Liabilities -$6.92M $2.95M $1.94M -$9.70M -$589,000.00
Net cash flow from investing -$119.63M -$206.29M $21.55M $27.89M -$104.84M
Net Cash Flow from Continuing Investing Activities -$119.63M -$206.29M $21.55M $27.89M -$104.84M
Net Intangibles Purchase and Sale -$141.87M -$21.07M -$22.18M -$58.16M -$19.24M
Net Investment Purchase and Sale $22.24M -$185.22M $43.73M $86.45M -$85.51M
Financing Cash Flow $27.29M $187.52M $4.20M -$33.47M $26.68M
Net Cash Flow from Continuing Financing Activities $27.29M $187.52M $4.20M -$33.47M $26.68M
Net Issuance Payments Of Debt $0.00 – – -$68.90M $0.00
Proceeds from Stock Option Exercised $27.89M $30.20M $4.73M $37.54M $27.20M
Net Other Financing Charges -$603,000.00 -$16.80M -$525,000.00 -$2.10M -$525,000.00
Ending Cash Balance $123.54M $117.74M $78.36M $93.04M $93.04M
Net Change in Cash $5.87M $39.30M -$14.61M $32.21M -$17.48M
Beginning Cash Balance $117.74M $78.36M $93.04M $58.54M $110.93M
Effect of Exchange Rate Changes -$59,000.00 $72,000.00 -$60,000.00 $2.29M -$413,000.00
Free Cash Flow -$43.66M $37.00M -$62.54M -$20.37M $41.81M
-Change In Other Working Capital – – – -$3.44M -$622,000.00
Cash Flow from Discontinued Operating Activities – – – $0.00 $0.00
Net Other Investing Changes – – – -$404,000.00 -$470,000.00
Net Common Stock Issuance – – – $0.00 –
Cash Flow from Discontinued Financing Activities – – – $0.00 –

Discussion

No comments yet — be the first to weigh in on TVTX.

Sign in to join the discussion.

Scroll to Top